Literature DB >> 37094

beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.

L A Salako, A O Falase, A Ragon, R A Adio.   

Abstract

The beta-adrenoceptor blocking effects of pindolol were compared with those of a placebo in a double-blind trial in twelve hypertensive Africans. Heart rate and arterial blood pressure were measured at rest and immediately after exercise, before and at intervals up to 8 h after oral administration of the drugs. Plasma levels of pindolol were also determined. Pindolol reduced systolic blood pressure and antagonised exercised-induced tachycardia. The mean time to peak level of pindolol was 1.9 h and the mean half-life was 4.2 h. Comparison of plasma levels of pindolol and beta-adrenoceptor blocking activity showed good correlation between them. It is concluded that the pharmacokinetics and beta-blocking effects of pindolol in Africans are not dissimilar from published data for other races.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37094     DOI: 10.1007/bf00558431

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man.

Authors:  R Gugler; W Höbel; G Bodem; H J Dengler
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

2.  Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.

Authors:  D Lavene; Y A Weiss; M E Safar; Y Loria; N Agorus; D Georges; P L Milliez
Journal:  J Clin Pharmacol       Date:  1977 Aug-Sep       Impact factor: 3.126

3.  Studies of cardioselectivity and partial agonist activity in beta-adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise.

Authors:  V M Oh; C M Kaye; S J Warrington; E A Taylor; J Wadsworth
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

4.  Defective cardiac parasympathetic control in patients with heart disease.

Authors:  D L Eckberg; M Drabinsky; E Braunwald
Journal:  N Engl J Med       Date:  1971-10-14       Impact factor: 91.245

5.  Pharmacokinetics of pindolol in man.

Authors:  R Gugler; W Herold; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  Prolonged action of pindolol.

Authors:  W H Aellig; K Saameli
Journal:  Br Med J       Date:  1973-05-12

7.  Effect of propranolol on elevated arterial blood pressure.

Authors:  D W Richardson; J Freund; A S Gear; H P Mauck; L W Preston
Journal:  Circulation       Date:  1968-04       Impact factor: 29.690

8.  Ineffectiveness of propranolol in hypertensive Jamaicans.

Authors:  G S Humphreys; D G Delvin
Journal:  Br Med J       Date:  1968-06-08

Review 9.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15
View more
  3 in total

Review 1.  The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks.

Authors:  J R M'Buyamba-Kabangu; M Tambwe
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

Review 2.  Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.

Authors:  Lizzy M Brewster; Yackoob K Seedat
Journal:  BMC Med       Date:  2013-05-30       Impact factor: 8.775

Review 3.  FIRST REPORTS OF CLINICAL PHARMACOKINETICS IN NIGERIA.

Authors:  O S Michael
Journal:  Ann Ib Postgrad Med       Date:  2015-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.